Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Aug;40(8):1811–1816. doi: 10.1128/aac.40.8.1811

Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.

M S Bartlett 1, W L Current 1, M P Goheen 1, C J Boylan 1, C H Lee 1, M M Shaw 1, S F Queener 1, J W Smith 1
PMCID: PMC163422  PMID: 8843286

Abstract

Cyclic lipodepsipeptide compounds of the echinocandin class exhibit broad-spectrum antifungal activity and have been shown to be effective in the treatment of Pneumocystis carinii pneumonia in laboratory animal models. Previous studies have led investigators to propose that these compounds, active against fungal cell walls, are selectively active against the cyst forms of P. carinii. We demonstrate that a semisynthetic, water-soluble echinocandin analog, LY307853, is effective in reducing the number of all life cycle forms of P. carinii and is more effective in mice immunosuppressed with monoclonal antibody to L3T4+ cells than in mice immunosuppressed with dexamethasone. Treatment of P. carinii isolates with LY307853 in a short-term in vitro culture model resulted in cytoarchitectural alterations suggesting that this echinocandin may interfere with the export of surface glycoprotein and the formation of the tubular elements normally found on the surfaces of trophic forms. The cytoarchitectural changes in trophic forms treated in vitro with LY307853 were also observed in trophic forms in the lung tissue of rats treated with a closely related echinocandin analog, LY303366.

Full Text

The Full Text of this article is available as a PDF (2.4 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett M. S., Current W. L., Orazi A., Bauer N. L., Neiman R. S., Queener S. F., Smith J. W. Comparison of corticosteroid- and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes. Clin Diagn Lab Immunol. 1994 Sep;1(5):511–516. doi: 10.1128/cdli.1.5.511-516.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartlett M. S., Edlind T. D., Lee C. H., Dean R., Queener S. F., Shaw M. M., Smith J. W. Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice. Antimicrob Agents Chemother. 1994 Aug;38(8):1834–1837. doi: 10.1128/aac.38.8.1834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartlett M. S., Fishman J. A., Queener S. F., Durkin M. M., Jay M. A., Smith J. W. New rat model of Pneumocystis carinii infection. J Clin Microbiol. 1988 Jun;26(6):1100–1102. doi: 10.1128/jcm.26.6.1100-1102.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bartlett M. S., Queener S. F., Durkin M. M., Shaw M. A., Smith J. W. Inoculated mouse model of Pneumocystis carinii infection. Diagn Microbiol Infect Dis. 1992 Feb;15(2):129–134. doi: 10.1016/0732-8893(92)90036-s. [DOI] [PubMed] [Google Scholar]
  5. Bartlett M. S., Verbanac P. A., Smith J. W. Cultivation of Pneumocystis carinii with WI-38 cells. J Clin Microbiol. 1979 Dec;10(6):796–799. doi: 10.1128/jcm.10.6.796-799.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boylan C. J., Current W. L. Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals. Infect Immun. 1992 Apr;60(4):1589–1597. doi: 10.1128/iai.60.4.1589-1597.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dialynas D. P., Wilde D. B., Marrack P., Pierres A., Wall K. A., Havran W., Otten G., Loken M. R., Pierres M., Kappler J. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev. 1983;74:29–56. doi: 10.1111/j.1600-065x.1983.tb01083.x. [DOI] [PubMed] [Google Scholar]
  8. Durkin M. M., Shaw M. M., Bartlett M. S., Smith J. W. Culture and filtration methods for obtaining Pneumocystis carinii trophozoites and cysts. J Protozool. 1991 Nov-Dec;38(6):210S–212S. [PubMed] [Google Scholar]
  9. Goheen M. P., Bartlett M. S., Current W. L., Shaw M. M., Smith J. W. Immuno electron microscopy of Pneumocystis carinii exposed to a beta-1-3 glucan synthase inhibitor LY 302146. J Eukaryot Microbiol. 1994 Sep-Oct;41(5):89S–89S. [PubMed] [Google Scholar]
  10. Goheen M. P., Blumershine R., Bartlett M. S., Hull M. T., Smith J. W. Improved intracellular morphology of Pneumocystis carinii from rat lung by postfixation with a mixture of potassium ferrocyanide and osmium tetroxide. Biotech Histochem. 1992 May;67(3):140–148. doi: 10.3109/10520299209110024. [DOI] [PubMed] [Google Scholar]
  11. Hughes W. T., McNabb P. C., Makres T. D., Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1974 Mar;5(3):289–293. doi: 10.1128/aac.5.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hunziker W., Whitney J. A., Mellman I. Brefeldin A and the endocytic pathway. Possible implications for membrane traffic and sorting. FEBS Lett. 1992 Jul 27;307(1):93–96. doi: 10.1016/0014-5793(92)80908-y. [DOI] [PubMed] [Google Scholar]
  13. Klausner R. D., Donaldson J. G., Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol. 1992 Mar;116(5):1071–1080. doi: 10.1083/jcb.116.5.1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lee C. H., Bauer N. L., Shaw M. M., Durkin M. M., Bartlett M. S., Queener S. F., Smith J. W. Proliferation of rat Pneumocystis carinii on cells sheeted on microcarrier beads in spinner flasks. J Clin Microbiol. 1993 Jun;31(6):1659–1662. doi: 10.1128/jcm.31.6.1659-1662.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med. 1992 Dec 24;327(26):1853–1860. doi: 10.1056/NEJM199212243272606. [DOI] [PubMed] [Google Scholar]
  16. Palluault F., Dei-Cas E., Slomianny C., Soulez B., Camus D. Golgi complex and lysosomes in rabbit derived Pneumocystis carinii. Biol Cell. 1990;70(1-2):73–82. doi: 10.1016/0248-4900(90)90362-7. [DOI] [PubMed] [Google Scholar]
  17. Phair J., Muñoz A., Detels R., Kaslow R., Rinaldo C., Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990 Jan 18;322(3):161–165. doi: 10.1056/NEJM199001183220304. [DOI] [PubMed] [Google Scholar]
  18. Saah A. J., Hoover D. R., Peng Y., Phair J. P., Visscher B., Kingsley L. A., Schrager L. K. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA. 1995 Apr 19;273(15):1197–1202. [PubMed] [Google Scholar]
  19. Schmatz D. M., Abruzzo G., Powles M. A., McFadden D. C., Balkovec J. M., Black R. M., Nollstadt K., Bartizal K. Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species. J Antibiot (Tokyo) 1992 Dec;45(12):1886–1891. doi: 10.7164/antibiotics.45.1886. [DOI] [PubMed] [Google Scholar]
  20. Schmatz D. M., Powles M. A., McFadden D. C., Pittarelli L., Balkovec J., Hammond M., Zambias R., Liberator P., Anderson J. Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats. Antimicrob Agents Chemother. 1992 Sep;36(9):1964–1970. doi: 10.1128/aac.36.9.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Schmatz D. M., Powles M. A., McFadden D., Nollstadt K., Bouffard F. A., Dropinski J. F., Liberator P., Andersen J. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Antimicrob Agents Chemother. 1995 Jun;39(6):1320–1323. doi: 10.1128/aac.39.6.1320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Schmatz D. M., Romancheck M. A., Pittarelli L. A., Schwartz R. E., Fromtling R. A., Nollstadt K. H., Vanmiddlesworth F. L., Wilson K. E., Turner M. J. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5950–5954. doi: 10.1073/pnas.87.15.5950. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES